800mg Darunavir tablets prepared by hot melt extrusion

Pharmaceutical Development and Technology

Volumn 16, Issue 6, 2011, Pages 645-650

  Thommes, Markus ^a   Baert, Lieven ^b   Rosier, Jan ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Chem Pharm Development   (Belgium)

Author keywords

Darunavir; Dissolution; Drug release; Hot melt extrusion; Poloxamer; Prezista

Indexed keywords

DARUNAVIR; MANNITOL; POLOXAMER; SOLUBILIZER; DRUG CARRIER; EXCIPIENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; SULFONAMIDE;

ARTICLE; CONTROLLED STUDY; DRUG RELEASE; DRUG SOLUBILITY; HOT MELT EXTRUSION; PELLET EXTRUSION; PRIORITY JOURNAL; TABLET DISINTEGRATION; TABLET FORMULATION; TABLET PROPERTY; TABLET SURFACE; CHEMISTRY; COMPARATIVE STUDY; HEAT; PARTICLE SIZE; SOLUBILITY; TABLET;

DRUG CARRIERS; EXCIPIENTS; HIV PROTEASE INHIBITORS; HOT TEMPERATURE; MANNITOL; PARTICLE SIZE; POLOXAMER; SOLUBILITY; SULFONAMIDES; TABLETS;

EID: 80755187586     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2010.508077     Document Type: Article

References (10)

1. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Tippeswamy D, Kincaid JF, Boross P, Wang Y F, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodefciency virus in vitro. Antimicrob. Agents Chemother 2003;47:3123-3129. (Pubitemid 37229567)
2. Tommes M, Baert L, van't Klooster G, Rosier J, Kleinebudde P. Improved bioavailability of darunavir by use of κ-carrageenan versus microcrystalline cellulose as pelletization aid. Eur J Pharm Biopharm 2009;72:614-620.
3. Ghebre-Sellassie I, Martin C. Pharmaceutical extrusion technology. New York: Marcel Dekker; 2003.
4. Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007;46:739-756. (Pubitemid 47347446)
5. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev 1997;23:3-25. (Pubitemid 27046991)
6. Van Gyseghem E, Stokbroekx S, de Armas HN, Dickens J, Vanstockem M, Baert L, Rosier J, Schueller L, Van den Mooter G. Solid state characterization of the anti-HIV drug TMC114: Interconversion of amorphous TMC114, TMC114 ethanolate and hydrate. Eur J Pharm Sci 2009;38:489-497.
7. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281-1302.
8. Newa M, Bhandari KH, Li DX, Kwon TH, Kim JA, Yoo BK, Woo JS, Lyoo WS, Yong CS, Choi HG. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int J Pharm 2007;343:228-237 (Pubitemid 47321028)
9. BASF. Lutrol. Product Data Sheat. 2008.
10. FDA. Poloxamer 188-oral tablets. Inactive ingredient list. LQA7B6G8JG. 2010.